Francine Durocher

List of Publications by Year in Descending Order

245 papers	14,455 citations	59 h-index	114 g-index
252 ext. papers	17,377 ext. citations	8 avg, IF	5.41 L-index

#	Paper	IF	Citations
245	DNA methylation of circadian genes and markers of cardiometabolic risk in female hospital workers: An exploratory study.. *Chronobiology International*, **2022**, 1-12	3.6	1
244	Abstract P5-06-11: Secreted frizzled related protein 1: From lobular involution to breast osteoimmunological disorder. *Cancer Research*, **2022**, 82, P5-06-11-P5-06-11	10.1	
243	Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?. *Cancers*, **2021**, 13,	6.6	1
242	TBC1D9: An Important Modulator of Tumorigenesis in Breast Cancer. *Cancers*, **2021**, 13,	6.6	1
241	PALB2 Variants: Protein Domains and Cancer Susceptibility. *Trends in Cancer*, **2021**, 7, 188-197	12.5	1
240	Associations between markers of mammary adipose tissue dysfunction and breast cancer prognostic factors. *International Journal of Obesity*, **2021**, 45, 195-205	5.5	3
239	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *British Journal of Cancer*, **2021**, 124, 842-854	8.7	2
238	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
237	Associations of Biomarkers of Inflammation and Breast Cancer in the Breast Adipose Tissue of Women with Combined Measures of Adiposity. *Journal of Obesity*, **2021**, 2021, 3620147	3.7	2
236	Breast Cancer Treatments: Updates and New Challenges. *Journal of Personalized Medicine*, **2021**, 11,	3.6	16
235	Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients. *Journal of Personalized Medicine*, **2021**, 11,	3.6	1
234	Epigenome-wide DNA methylation and risk of breast cancer: a systematic review. *BMC Cancer*, **2020** , 20, 1048	4.8	6
233	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
232	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nature Reviews Clinical Oncology*, **2020**, 17, 687-705	19.4	64
231	Machine learning analysis identifies genes differentiating triple negative breast cancers. *Scientific Reports*, **2020**, 10, 10464	4.9	14
230	Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. *Biostatistics*, **2020**, 21, 518-530	3.7	1
229	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25

228	Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines. *PLoS ONE*, **2020**, 15, e0234991	3.7	7
227	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
226	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 368-378	4	9
225	Role of Secreted Frizzled-Related Protein 1 in Early Mammary Gland Tumorigenesis and Its Regulation in Breast Microenvironment. *Cells*, **2020**, 9,	7.9	6
224	Association Between BMI and DNA Methylation in Blood or Normal Adult Breast Tissue: A Systematic Review. *Anticancer Research*, **2020**, 40, 1797-1808	2.3	5
223	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
222	Survey of primary care physiciansNviews about breast and ovarian cancer screening for true BRCA1/2 non-carriers. *Journal of Community Genetics*, **2020**, 11, 205-213	2.5	0
221	Functional characterization of 84 PALB2 variants of uncertain significance. *Genetics in Medicine*, **2020**, 22, 622-632	8.1	20
220	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
219	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. *International Journal of Epidemiology*, **2020**, 49, 1117-1131	7.8	17
218	Estrogens and Glucocorticoids in Mammary Adipose Tissue: Relationships with Body Mass Index and Breast Cancer Features. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	4
217	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
216	Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
215	DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood. *Cancers*, **2020**, 12,	6.6	8
214	Secreted Frizzled-Related Protein 1 as a Biomarker against Incomplete Age-Related Lobular Involution and MicrocalcificationsNDevelopment. *Cancers*, **2020**, 12,	6.6	2
213	The Importance of Breast Adipose Tissue in Breast Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	30
212	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. *International Journal of Cancer*, **2020**, 146, 2130-2138	7.5	9
211	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. *EBioMedicine*, **2019**, 48, 203-211	8.8	9

210	Simultaneous quantification of estrogens and glucocorticoids in human adipose tissue by liquid-chromatography-tandem mass spectrometry. *Journal of Steroid Biochemistry and Molecular Biology*, **2019**, 195, 105476	5.1	10
209	Mass spectra alignment using virtual lock-masses. *Scientific Reports*, **2019**, 9, 8469	4.9	5
208	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
207	AuthorsNresponse: Associations of obesity and circulating insulin and glucose with breast cancer risk. *International Journal of Epidemiology*, **2019**, 48, 1016-1017	7.8	
206	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. *International Journal of Epidemiology*, **2019**, 48, 1727-1730	7.8	1
205	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
204	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. *European Journal of Epidemiology*, **2019**, 34, 591-600	12.1	11
203	Open science precision medicine in Canada: Points to consider. *Facets*, **2019**, 4, 1-19	2.3	4
202	Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives. *Healthcare Policy*, **2019**, 15, 39-54	1.1	7
201	A response to "Personalised medicine and population health: breast and ovarian cancer". *Human Genetics*, **2019**, 138, 287-289	6.3	13
200	A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. *Nucleic Acids Research*, **2019**, 47, 10662-10677	20.1	22
199	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. *International Journal of Cancer*, **2019**, 144, 1195-1204	7.5	18
198	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
197	The Tumor Suppressor PALB2: Inside Out. *Trends in Biochemical Sciences*, **2019**, 44, 226-240	10.3	56
196	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*, **2019**, 21, 1708-1718	8.1	192
195	Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening. *New Genetics and Society*, **2019**, 38, 38-59	1.9	6
194	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2019**, 48, 795-806	7.8	52
193	Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada). *BMJ Open*, **2018**, 8, e016662	3	5

192	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
191	On the readiness of physicians for pharmacogenomics testing: an empirical assessment. *Pharmacogenomics Journal*, **2018**, 18, 308-318	3.5	20
190	Inherited mutations in and in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. *Journal of Medical Genetics*, **2018**, 55, 97-103	5.8	24
189	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
188	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
187	Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy. *Oncotarget*, **2018**, 9, 37407-37420	3.3	19
186	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. *Cancer Research*, **2018**, 78, 6329-6338	10.1	13
185	An isoform of AIF1 involved in breast cancer. *Cancer Cell International*, **2018**, 18, 167	6.4	5
184	Adiposity, breast density, and breast cancer risk: epidemiological and biological considerations. *European Journal of Cancer Prevention*, **2017**, 26, 511-520	2	29
183	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
182	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
181	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
180	No evidence of excessive cancer screening in female noncarriers from mutation-positive families. *Current Oncology*, **2017**, 24, 352-359	2.8	1
179	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
178	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. *International Journal of Cancer*, **2017**, 141, 1830-1840	7.5	13
177	Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?. *American Journal of Preventive Medicine*, **2017**, 53, e195-e196	6.1	5
176	Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 425-427	4	4
175	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15

174	Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?. *Familial Cancer*, **2017**, 16, 35-40	3	4
173	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
172	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. *Frontiers in Genetics*, **2017**, 8, 128	4.5	13
171	Transcriptional signature of lymphoblastoid cell lines of , and non- high risk breast cancer families. *Oncotarget*, **2017**, 8, 78691-78712	3.3	6
170	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
169	The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. *Familial Cancer*, **2016**, 15, 1-17	3	7
168	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
167	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Human Molecular Genetics*, **2016**, 25, 3863-3876	5.6	24
166	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
165	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
164	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
163	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
162	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
161	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Medicine*, **2016**, 13, e1002105	11.6	80
160	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
159	ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. *PLoS ONE*, **2016**, 11, e0156820	3.7	3
158	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS ONE*, **2016**, 11, e0160316	3.7	11
157	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26

156	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
155	Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. *Genetics in Medicine*, **2016**, 18, 627-34	8.1	4
154	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. *Genetics in Medicine*, **2016**, 18, 1190-1198	8.1	64
153	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes and Control*, **2016**, 27, 679-93	2.8	15
152	Usefulness of Canadian Public Health Insurance Administrative Databases´to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers. *Canadian Association of Radiologists Journal*, **2016**, 67, 308-312	3.9	3
151	Genome-wide methylation analysis of DNMT3B gene isoforms revealed specific methylation profiles in breast cell lines. *Epigenomics*, **2016**, 8, 1209-26	4.4	3
150	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *American Journal of Human Genetics*, **2016**, 99, 903-911	11	43
149	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis*, **2015**, 36, 256-71	4.6	12
148	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
147	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406
146	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *American Journal of Human Genetics*, **2015**, 97, 22-34	11	26
145	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
144	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. *Cancer Research*, **2015**, 75, 2457-67	10.1	45
143	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
142	Analysis of a FANCE Splice Isoform in Regard to DNA Repair. *Journal of Molecular Biology*, **2015**, 427, 3056-73	6.5	10
141	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1680-91	4	17
140	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
139	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20

138	SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation. *Genetic Epidemiology*, **2015**, 39, 406-14	2.6	5
137	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
136	SNP-SNP interaction analysis of NF-B signaling pathway on breast cancer survival. *Oncotarget*, **2015**, 6, 37979-94	3.3	19
135	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84	5.6	36
134	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics*, **2015**, 96, 5-20	11	59
133	The Role of Methylation in Breast Cancer Susceptibility and Treatment. *Anticancer Research*, **2015**, 35, 4569-74	2.3	22
132	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46	5.6	28
131	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genetic Epidemiology*, **2014**, 38, 84-93	2.6	24
130	Life insurance: genomic stratification and risk classification. *European Journal of Human Genetics*, **2014**, 22, 575-9	5.3	31
129	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *British Journal of Cancer*, **2014**, 110, 1088-100	8.7	20
128	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46	5.6	11
127	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
126	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genetics*, **2014**, 10, e1004285	6	38
125	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
124	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
123	Family communication following BRCA1/2 genetic testing: a close look at the process. *Journal of Genetic Counseling*, **2013**, 22, 323-35	2.5	21
122	Life events may contribute to family communication about cancer risk following BRCA1/2 testing. *Journal of Genetic Counseling*, **2013**, 22, 249-57	2.5	12
121	Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. *European Journal of Human Genetics*, **2013**, 21, 903-10	5.3	13

120	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *American Journal of Human Genetics*, **2013**, 93, 1046-60	11	80
119	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
118	Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population. *Molecular Oncology*, **2013**, 7, 85-100	7.9	22
117	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American Journal of Human Genetics*, **2013**, 92, 489-503	11	167
116	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2	36.3	327
115	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, **2013**, 45, 353-61, 361e1-2	36.3	813
114	A focus group study on breast cancer risk presentation: one format does not fit all. *European Journal of Human Genetics*, **2013**, 21, 719-24	5.3	14
113	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
112	Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families. *Journal of Human Genetics*, **2013**, 58, 59-66	4.3	4
111	Lessons learned and challenges posed in cancer genetics. Introduction. *Journal of Internal Medicine*, **2013**, 274, 396-8	10.8	
110	Personalized medicine and access to health care: potential for inequitable access?. *European Journal of Human Genetics*, **2013**, 21, 143-7	5.3	33
109	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
108	Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. *Familial Cancer*, **2012**, 11, 27-32	3	8
107	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
106	Functional analysis of promoter variants in KU70 and their role in cancer susceptibility. *Genes Chromosomes and Cancer*, **2012**, 51, 1007-13	5	6
105	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. *British Journal of Cancer*, **2012**, 106, 2016-24	8.7	25
104	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
103	Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study. *Genetics in Medicine*, **2012**, 14, 60-8	8.1	7

102	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
101	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
100	Systematic mixed-methods reviews are not ready to be assessed with the available tools. *Journal of Clinical Epidemiology*, **2011**, 64, 926-8	5.7	7
99	Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. *European Journal of Human Genetics*, **2011**, 19, 494-9	5.3	14
98	The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 126, 521-7	4.4	3
97	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
96	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1032-8	4	13
95	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
94	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
93	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
92	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
91	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32
90	Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. *Genetic Testing and Molecular Biomarkers*, **2010**, 14, 515-26	1.6	23
89	Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2010**, 122, 281-5	4.4	5
88	Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer. *Journal of Human Genetics*, **2009**, 54, 152-61	4.3	36
87	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
86	Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 601-10	4	110
85	Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer. *BMC Cancer*, **2009**, 9, 181	4.8	32

84	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. *Breast Cancer Research and Treatment*, **2009**, 115, 185-92	4.4	11
83	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2009**, 101, 1456-60	8.7	17
82	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *British Journal of Cancer*, **2009**, 101, 2048-54	8.7	13
81	Fine temporal analysis of DHT transcriptional modulation of the ATM/Gadd45g signaling pathways in the mouse uterus. *Molecular Reproduction and Development*, **2009**, 76, 278-88	2.6	8
80	Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. *Journal of Steroid Biochemistry and Molecular Biology*, **2009**, 116, 134-53	5.1	11
79	Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. *Journal of Steroid Biochemistry and Molecular Biology*, **2008**, 109, 115-28	5.1	6
78	Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. *Journal of Molecular Endocrinology*, **2008**, 40, 161-72	4.5	11
77	Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. *Journal of Genetic Counseling*, **2008**, 17, 314-26	2.5	31
76	Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer. *Journal of Human Genetics*, **2008**, 53, 490-498	4.3	7
75	Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. *Journal of Human Genetics*, **2008**, 53, 579	4.3	33
74	Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. *International Journal of Cancer*, **2008**, 122, 108-16	7.5	17
73	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
72	Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. *Familial Cancer*, **2007**, 6, 483-90	3	23
71	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. *Journal of Human Genetics*, **2007**, 52, 963-977	4.3	10
70	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. *Journal of Medical Genetics*, **2007**, 44, 107-21	5.8	58
69	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 1416-21	4	26
68	Temporal analysis of E2 transcriptional induction of PTP and MKP and downregulation of IGF-I pathway key components in the mouse uterus. *Physiological Genomics*, **2007**, 29, 13-23	3.6	23
67	Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. *Genetic Testing and Molecular Biomarkers*, **2007**, 11, 45-54		37

66	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
65	Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. *BMC Cancer*, **2006**, 6, 230	4.8	38
64	Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility. *Psychological Reports*, **2006**, 98, 873-81	1.6	3
63	The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 76-9	4	24
62	Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS CollaboratorsNGroup. *Journal of Clinical Oncology*, **2006**, 24, 3361-6	2.2	150
61	No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. *Genetic Testing and Molecular Biomarkers*, **2006**, 10, 104-15		43
60	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. *Breast Cancer Research*, **2006**, 8, R3	8.3	64
59	Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. *Nutrition and Cancer*, **2006**, 54, 157-65	2.8	12
58	The emergence of an ethical duty to disclose genetic research results: international perspectives. *European Journal of Human Genetics*, **2006**, 14, 1170-8	5.3	221
57	Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges. *Familial Cancer*, **2006**, 5, 3-13	3	11
56	A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. *American Journal of Human Genetics*, **2005**, 77, 219-29	11	129
55	Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads. *Journal of Steroid Biochemistry and Molecular Biology*, **2005**, 97, 289-98	5.1	3
54	A new alternative splice variant of BRCA1 containing an additional in-frame exon. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2005**, 1731, 57-65		11
53	Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. *Human Genetics*, **2005**, 117, 119-32	6.3	44
52	GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. *Molecular Endocrinology*, **2005**, 19, 2358-70		78
51	Is dehydroepiandrosterone a hormone?. *Journal of Endocrinology*, **2005**, 187, 169-96	4.7	368
50	17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister. *Journal of Pediatric Endocrinology and Metabolism*, **2005**, 18, 403-11	1.6	9
49	Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?. *Cancer Research*, **2004**, 64, 840-3	10.1	44

48	Prostate cancer susceptibility genes: lessons learned and challenges posed. *Endocrine-Related Cancer*, **2003**, 10, 225-59	5.7	71
47	Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. *Journal of Steroid Biochemistry and Molecular Biology*, **2003**, 87, 167-79	5.1	23
46	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. *Journal of Lipid Research*, **2003**, 44, 1508-14	6.3	24
45	Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. *Molecular Endocrinology*, **2002**, 16, 1696-710		32
44	Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. *Seminars in Reproductive Medicine*, **2002**, 20, 255-76	1.4	51
43	Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene. *Journal of Steroid Biochemistry and Molecular Biology*, **2002**, 82, 55-63	5.1	26
42	DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. *Frontiers in Neuroendocrinology*, **2001**, 22, 185-212	8.9	267
41	A candidate prostate cancer susceptibility gene at chromosome 17p. *Nature Genetics*, **2001**, 27, 172-80	36.3	469
40	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. *Advances in Protein Chemistry*, **2001**, 56, 293-368		13
39	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. *Molecular and Cellular Endocrinology*, **2001**, 171, 25-40	4.4	38
38	Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 76, 213-25	5.1	20
37	EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 79, 213-25	5.1	40
36	Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. *Pharmacogenetics and Genomics*, **2001**, 11, 325-30		72
35	High risk genes predisposing to prostate cancer development-do they exist?. *Prostate Cancer and Prostatic Diseases*, **2000**, 3, 241-247	6.2	20
34	Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. *Carcinogenesis*, **2000**, 21, 189-93	4.6	60
33	A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency. *Endocrine Research*, **2000**, 26, 761-70	1.9	16
32	The extent of linkage disequilibrium in four populations with distinct demographic histories. *American Journal of Human Genetics*, **2000**, 67, 1544-54	11	170
31	Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. *Trends in Endocrinology and Metabolism*, **2000**, 11, 421-7	8.8	109

30	A Novel A10E Homozygous Mutation in the HSD3B2 Gene Causing Severe Salt-Wasting 3´-Hydroxysteroid Dehydrogenase Deficiency in 46,XX and 46,XY French-Canadians: Evaluation of Gonadal Function after Puberty. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 1968-1974	5.6	27
29	Multiple Signaling Pathways Mediate Interleukin-4-Induced 3´-Hydroxysteroid Dehydrogenase/´5-´4 Isomerase Type 1 Gene Expression in Human Breast Cancer Cells. *Molecular Endocrinology*, **2000**, 14, 229-240		13
28	p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. *Nucleic Acids Research*, **1999**, 27, 2722-9	20.1	113
27	No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. *Carcinogenesis*, **1999**, 20, 2131-5	4.6	96
26	Parallel solid-phase synthesis of a model library of 7alpha-alkylamide estradiol derivatives as potential estrogen receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 2827-32	2.9	21
25	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. *Journal of Steroid Biochemistry and Molecular Biology*, **1999**, 69, 51-84	5.1	149
24	17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. *Journal of Molecular Endocrinology*, **1999**, 23, 1-11	4.5	263
23	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. *Atherosclerosis*, **1999**, 143, 145-51	3.1	20
22	New Insight into the Molecular Basis of 3´-Hydroxysteroid Dehydrogenase Deficiency: Identification of Eight Mutations in the HSD3B2 Gene in Eleven Patients from Seven New Families and Comparison of the Functional Properties of Twenty-Five Mutant Enzymes. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 4410-4425	5.6	71
21	Induction of 3´-Hydroxysteroid Dehydrogenase/´5-´4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. *Molecular Endocrinology*, **1999**, 13, 66-81		46
20	BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey. *Annals of the New York Academy of Sciences*, **1998**, 839, 444-6	6.5	
19	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **1998**, 65, 151-62	5.1	28
18	Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. *American Journal of Human Genetics*, **1998**, 62, 653-8	11	112
17	Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1007-12	9.4	71
16	Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. *Pharmacogenetics and Genomics*, **1998**, 8, 49-53		14
15	Localization of BRCA1 gene expression in adult cynomolgus monkey tissues. *Journal of Histochemistry and Cytochemistry*, **1997**, 45, 1173-88	3.4	8
14	Response of Symbiotic Endomycorrhizal Fungi to Estrogens and Antiestrogens. *Molecular Plant-Microbe Interactions*, **1997**, 10, 481-487	3.6	39
13	(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. *Journal of Medicinal Chemistry*, **1997**, 40, 2117-22	8.3	131

12	Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. *Urology*, **1997**, 49, 580-6; discussion 586-9	1.6	35
11	Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. *International Journal of Cancer*, **1997**, 73, 104-12	7.5	53
10	Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. *Journal of Medical Genetics*, **1996**, 33, 814-9	5.8	30
9	Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22. *Cytogenetic and Genome Research*, **1996**, 73, 304-7	1.9	14
8	Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. *Human Molecular Genetics*, **1996**, 5, 835-42	5.6	81
7	The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. *DNA and Cell Biology*, **1995**, 14, 849-61	3.6	61
6	Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. *Genomics*, **1995**, 25, 724-6	4.3	24
5	Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21. *Genomics*, **1995**, 28, 530-42	4.3	39
4	Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region. *Genomics*, **1995**, 29, 781-3	4.3	11
3	Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family. *Journal of Steroid Biochemistry and Molecular Biology*, **1995**, 55, 489-505	5.1	25
2	Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. *Nature Genetics*, **1994**, 8, 392-8	36.3	285
1	Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family. *Molecular and Cellular Endocrinology*, **1994**, 103, 29-38	4.4	8